down arrow

Revolution Medicines, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US76155X1000
USD
78.48
3.17 (4.21%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Chromadex Corp.
Nature's Sunshine Products, Inc.
LifeVantage Corp.
Upexi, Inc.
Natural Alternatives International, Inc.
ProPhase Labs, Inc.
USANA Health Sciences, Inc.
Revolution Medicines, Inc.
Cidara Therapeutics, Inc.
MIRA Pharmaceuticals, Inc.
Bright Green Corp.
Why is Revolution Medicines, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
Icon
No Data Found
Is Revolution Medicines, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Revolution Medicines, Inc.
62.72%
1.94
47.23%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-254.91%
EBIT to Interest (avg)
-390.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.02
Tax Ratio
0.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.68
EV to EBIT
-7.05
EV to EBITDA
-7.16
EV to Capital Employed
-481.90
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-33.70%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
NET PROFIT(HY)

Higher at USD -459.06 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

CASH AND EQV(HY)

Highest at USD 4,239.85 MM

DEBT-EQUITY RATIO (HY)

Lowest at -107.45 %

-24What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -684.91 MM

ROCE(HY)

Lowest at -46.61%

OPERATING PROFIT(Q)

Lowest at USD -260.91 MM

PRE-TAX PROFIT(Q)

Lowest at USD -243.21 MM

NET PROFIT(Q)

Lowest at USD -243.21 MM

EPS(Q)

Lowest at USD -1.31

Here's what is working for Revolution Medicines, Inc.
Cash and Eqv
Highest at USD 4,239.85 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -107.45 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 3.8 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Revolution Medicines, Inc.
Operating Cash Flow
Lowest at USD -684.91 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit
Lowest at USD -260.91 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite negative

Operating Profit (USD MM)

Pre-Tax Profit
Lowest at USD -243.21 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit
At USD -243.21 MM has Fallen at -38.76%
over average net sales of the previous four periods of USD -175.28 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -243.21 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Profit
At USD -243.21 MM has Fallen at -38.9%
over average net sales of the previous four periods of USD -175.09 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

EPS
Lowest at USD -1.31
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."